In a report issued on July 13, Ian Hilliker from Jefferies maintained a Buy rating on Johnson & Johnson (NYSE: JNJ), with a price target of $145. The company’s shares closed on Friday at $125.93.
According to TipRanks.com, Hilliker is a 2-star analyst with an average return of 2.4% and a 64.3% success rate. Hilliker covers the Healthcare sector, focusing on stocks such as Merck & Company, Eli Lilly & Co, and Bristol Myers.
Currently, the analyst consensus on Johnson & Johnson is a Moderate Buy with an average price target of $142.10, implying a 12.8% upside from current levels. In a report issued on July 10, BMO Capital also reiterated a Buy rating on the stock with a $150 price target.
.
See today’s analyst top recommended stocks >>
Based on Johnson & Johnson’s latest earnings release for the quarter ending March 31, the company reported a quarterly revenue of $19.98 billion and net profit of $4.37 billion. In comparison, last year the company earned revenue of $18.85 billion and had a net profit of $3.83 billion.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
